CAMERON KAMRAN TEBBI, M.D.
Medical Practice in Tampa, FL
License number
Florida ME42258
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
2
2 Tampa General Cir Stc FLOOR 2ND, Tampa, FL 33606
PO Box 197770, Orlando, FL 32891
PO Box 197770, Orlando, FL 32891
Phone
(813) 259-8700
(813) 259-8862 (Fax)
(813) 259-8862 (Fax)
Personal information
See more information about CAMERON KAMRAN TEBBI at radaris.comName
Address
Phone
4019 Carrollwood Village Dr, Tampa, FL 33618
3001 Dr Martin Luther King Jr Blvd, Tampa, FL 33607
3319 Handy Rd, Tampa, FL 33618
4019 Carrollwood Palm Ct, Tampa, FL 33624
5126 Longfellow Ave, Tampa, FL 33629
Professional information
See more information about CAMERON KAMRAN TEBBI at trustoria.com
Dr. Cameron K Tebbi, Tampa FL - MD (Doctor of Medicine)
Dr. Cameron K Tebbi, Tampa FL - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
University Sth Flrda Physc Grp
17 Davis Blvd SUITE 100, Tampa 33606
(813) 259-8700 (Phone)
USF Physicians Group Pediatrics
2 Tampa General Cir SUITE 2, Tampa 33606
(813) 259-8700 (Phone)
17 Davis Blvd SUITE 100, Tampa 33606
(813) 259-8700 (Phone)
USF Physicians Group Pediatrics
2 Tampa General Cir SUITE 2, Tampa 33606
(813) 259-8700 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 1980, Pediatrics, 1974
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Sth Flrda Physc Grp
17 Davis Blvd SUITE 100, Tampa 33606
USF Physicians Group Pediatrics
2 Tampa General Cir SUITE 2, Tampa 33606
Saint Joseph's Hospital
3001 West Dr Martin Luther King Jr Blvd, Tampa 33607
Tampa General Hospital
1 Tampa General Cir, Tampa 33606
17 Davis Blvd SUITE 100, Tampa 33606
USF Physicians Group Pediatrics
2 Tampa General Cir SUITE 2, Tampa 33606
Saint Joseph's Hospital
3001 West Dr Martin Luther King Jr Blvd, Tampa 33607
Tampa General Hospital
1 Tampa General Cir, Tampa 33606
Education:
Medical School
Iran University of Medical Sciences / Faculty of Medicine
Jewish Hosp
Childrens Hospital Medical Center
Ontario Canc Inst
St Louis Childrens Hospital
Univ Of Tex MD Anderson Cancer Center
Iran University of Medical Sciences / Faculty of Medicine
Jewish Hosp
Childrens Hospital Medical Center
Ontario Canc Inst
St Louis Childrens Hospital
Univ Of Tex MD Anderson Cancer Center
Methods Of Detecting Susceptibility To Leukemia/ Lymphoma And Induction Of Leukemia And Lymphomas
Methods Of Detecting Susceptibility To Leukemia/ Lymphoma And Induction Of Leukemia And Lymphomas
US Patent:
2012015, Jun 21, 2012
Filed:
Dec 20, 2010
Appl. No.:
12/973153
Inventors:
Cameron K. Tebbi - Tampa FL, US
International Classification:
C40B 30/04, G01N 33/574, C12N 5/09, C12Q 1/70
US Classification:
506 9, 435 5, 435 721, 435 792, 435375
Abstract:
A diagnostic test is described using fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Detection of the leukemic transformation by means known in the art, identified patients who have or had leukemia, or potentially may become leukemic. Unlike aflotoxin, which indiscriminately induces leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of ALL and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. These findings have implications for the etiology of leukemias and lymphomas. This invention can potentially be used for mass screening, detection of susceptible individuals to leukemia and ultimately their vaccination.
Methods Of Inducing Leukemia And Lymphomas And Detecting Susceptibility To Leukemia/ Lymphoma
Methods Of Inducing Leukemia And Lymphomas And Detecting Susceptibility To Leukemia/ Lymphoma
US Patent:
2013013, May 30, 2013
Filed:
Nov 9, 2012
Appl. No.:
13/673301
Inventors:
Cameron K. Tebbi - Tampa FL, US
International Classification:
C12N 5/09
US Classification:
435375
Abstract:
A diagnostic test is described using fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Detection of the leukemic transformation by means known in the art, identified patients who have or had leukemia, or potentially may become leukemic. Unlike aflatoxins, which indiscriminately induce leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of acute lymphoblastic leukemia (ALL) and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. The combination of cultures of EBV and , with and without radiation, results in the development of a new protein peak which is superior in observed results. These findings have implications for the etiology of leukemias and lymphomas. This invention can potentially be used for mass screening, detection of susceptible individuals to leukemia and ultimately their vaccination.